A new series of vinyl amide-, imidazolone-, and triazinone-linked combretastatin A-4 analogues have been designed and synthesised. These compounds have been evaluated for their cytotoxic activity against MDA-MB-231 breast cancer cells. The triazinone-linked combretastatin analogues (6 and 12) exhibited the most potent cytotoxic activity, in sub-micromolar concentration compared with combretastatin A-4 as a reference standard. The results of β-tubulin polymerisation inhibition assay appear to correlate well with the ability to inhibit β-tubulin polymerisation. Additionally, these compounds were subjected to biological assays relating to cell cycle aspects and apoptosis induction. In addition, the most potent compound 6 was loaded on PEG-PCL ...
Thirteen methylpyrazoline analogs (1a-m) of combretastatin A-4 (CA-4, 2) were synthesized. The trans...
We have synthesized rigid analogues of combretastatin bearing a furan ring in place of the olefinic ...
Combretastatin A-4 (CA-4) is an anti-mitotic agent that is gaining rapid recognition among cancer bi...
Twenty-three combretastatin A-4 (CA-4) analogues were synthesized by judiciously incorporating a fun...
Twenty-three combretastatin A-4 (CA-4) analogues were synthesized by judiciously incorporating a fun...
A series of 1-aryl-5-(3′,4′,5′-trimethoxyphenyl) derivatives and their related 1-(3′,4′,5′-trimethox...
A new series of combretastatin analogues with B-ring modifications were synthesized and evaluated fo...
Combretastatin A-4 (CA-4) is a potent tubulin polymerisation inhibitor. However, the clinical applic...
A series of combretastatin derivatives were designed and synthesised by a two-step stereoselective s...
Combretastatin A-4 (CA-4) in phosphate and serine pro-drug forms is under phase II clinical trials. ...
International audienceTo find new and better antivascular agents for cancer therapy, a series of com...
International audienceWe have synthesized a large variety of CA-4 analogues having a non-isomerizabl...
A novel series of tubulin polymerization inhibitors, based on the 1-(3’,4’,5’-trimethoxyphenyl)-2-ar...
Two new series of combretastatin (CA-4) analogues have been prepared. The alkenyl motif of CA-4 was ...
Two new series of combretastatin (CA-4) analogues have been prepared. The alkenyl motif of CA-4 was ...
Thirteen methylpyrazoline analogs (1a-m) of combretastatin A-4 (CA-4, 2) were synthesized. The trans...
We have synthesized rigid analogues of combretastatin bearing a furan ring in place of the olefinic ...
Combretastatin A-4 (CA-4) is an anti-mitotic agent that is gaining rapid recognition among cancer bi...
Twenty-three combretastatin A-4 (CA-4) analogues were synthesized by judiciously incorporating a fun...
Twenty-three combretastatin A-4 (CA-4) analogues were synthesized by judiciously incorporating a fun...
A series of 1-aryl-5-(3′,4′,5′-trimethoxyphenyl) derivatives and their related 1-(3′,4′,5′-trimethox...
A new series of combretastatin analogues with B-ring modifications were synthesized and evaluated fo...
Combretastatin A-4 (CA-4) is a potent tubulin polymerisation inhibitor. However, the clinical applic...
A series of combretastatin derivatives were designed and synthesised by a two-step stereoselective s...
Combretastatin A-4 (CA-4) in phosphate and serine pro-drug forms is under phase II clinical trials. ...
International audienceTo find new and better antivascular agents for cancer therapy, a series of com...
International audienceWe have synthesized a large variety of CA-4 analogues having a non-isomerizabl...
A novel series of tubulin polymerization inhibitors, based on the 1-(3’,4’,5’-trimethoxyphenyl)-2-ar...
Two new series of combretastatin (CA-4) analogues have been prepared. The alkenyl motif of CA-4 was ...
Two new series of combretastatin (CA-4) analogues have been prepared. The alkenyl motif of CA-4 was ...
Thirteen methylpyrazoline analogs (1a-m) of combretastatin A-4 (CA-4, 2) were synthesized. The trans...
We have synthesized rigid analogues of combretastatin bearing a furan ring in place of the olefinic ...
Combretastatin A-4 (CA-4) is an anti-mitotic agent that is gaining rapid recognition among cancer bi...